Oliver N Keene

Alternatives to the hazard ratio in summarizing efficacy in time‐to‐event studies: an example from influenza trials

Oliver N Keene, O. Keene, 2002, Statistics in medicine.

Once-daily valacyclovir to reduce the risk of transmission of genital herpes*

Lawrence Corey, Jorma Paavonen, Gregory Mertz, 2004, The New England journal of medicine.

Missing data sensitivity analysis for recurrent event data using controlled imputation.

Michael G Kenward, James H Roger, Oliver N Keene, 2014, Pharmaceutical statistics.

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

Ian D Pavord, Peter Howarth, Stephanie Korn, 2012, The Lancet.

Biomarkers for severe eosinophilic asthma

Oliver N Keene, I. Pavord, E. Bleecker, 2017, The Journal of allergy and clinical immunology.

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.

Christopher E Brightling, Ian D Pavord, Oliver N Keene, 2016, The Lancet. Respiratory medicine.

Intent‐to‐treat analysis in the presence of off‐treatment or missing data

Oliver N Keene, O. Keene, 2011, Pharmaceutical statistics.

Mepolizumab treatment in patients with severe eosinophilic asthma.

Ian D Pavord, Marc Humbert, Oliver N Keene, 2014, The New England journal of medicine.

Lamivudine for patients with chronic hepatitis B and advanced liver disease.

Oliver N Keene, J. Sung, Y. Liaw, 2004, The New England journal of medicine.